Monica Ronzoni - Concepedia

Author

Monica Ronzoni

Istituti di Ricovero e Cura a Carattere Scientifico ORCID

Also Known As

Al B. Benson III, M Ronzoni, M. RONZONI, M. Ronzoni, Mauro Ronzoni, Monica Ronzoni, Ronzoni, Monica, Vincenzo Ricci

166

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico Istituto Oncologico Veneto IRCCS Ospedale San Raffaele Azienda Ospedaliera Universitaria Pisana University of Pisa

About

Monica Ronzoni is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in oncology, medicine, and colorectal cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	31	2.5K
2	Health Sciences	11	12	499
3	Gastroenterology	5	7	206
4	Engineering	1	1	21
5	Cell Biology	1	1	21

Monica Ronzoni

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, The Lancet Oncology Phase 3Gastrointestinal OncologyMedicinePathologyColorectal Cancer	2015	1.1K
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer Fotios Loupakis, Chiara Cremolini, Gianluca Masi, New England Journal of Medicine	2014	1.1K
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer Stephen Chan, Kay Friedrichs, D. Noel, Journal of Clinical Oncology	1999	638
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, The Lancet Oncology OncologyMedicineColorectal CancerPathologyUpfront Folfoxiri	2020	309
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO Emanuela Dell’Aquila, Chiara Cremolini, Tea Zeppola, Annals of Oncology	2018	134
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi, JAMA Oncology	2018	111
Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients Monica Ronzoni, M. Manzoni, S. Mariucci, Annals of Oncology Bevacizumab-based First-line TreatmentEndothelial CellsEndothelial ProgenitorsMedicineImmunology	2010	107
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi, Annals of Oncology	2018	104
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer M. Manzoni, B. Rovati, Monica Ronzoni, Oncology	2010	88
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. Alfredo Falcone, Chiara Cremolini, Gianluca Masi, Journal of Clinical Oncology PathologyGono GroupFirst-line TreatmentPharmacotherapyMetronomic Chemotherapy	2013	75

Page 1